Idiopathic Retroperitoneal Fibrosis Ormond Disease: Periaortic Fibroinflammatory Plaque Ureteric Obstruction and IgG4 Overlap
A rare chronic fibroinflammatory disorder characterized by a fibrous plaque encasing the abdominal aorta, common iliac arteries, and adjacent retroperitoneal structures — frequently producing ureteric encasement with progressive obstructive uropathy, recognized increasingly as part of the IgG4-related disease spectrum in approximately 50% of cases, and managed through ureteric drainage for acute obstruction combined with glucocorticoid therapy as cornerstone medical management and emerging rituximab and methotrexate options for refractory or steroid-dependent disease.
S1. Pathophysiology and IgG4 Overlap Spectrum
Idiopathic retroperitoneal fibrosis (IRF) — also known as Ormond disease after John Ormond’s 1948 description of the condition’s modern clinicopathologic characterization — is a rare chronic fibroinflammatory disorder characterized by a fibrous plaque encasing the abdominal aorta, common iliac arteries, and adjacent retroperitoneal structures including the ureters, inferior vena cava, and mesenteric vessels. The disease’s defining anatomic feature is the dense fibrous tissue surrounding the infrarenal aorta and extending laterally to encase the ureters at the level of the pelvic brim, producing the characteristic obstructive uropathy that dominates clinical presentation in most patients.
Contemporary understanding has substantially evolved with the recognition that approximately 50% of IRF cases represent the retroperitoneal manifestation of IgG4-related disease (IgG4-RD), a multi-organ fibroinflammatory disorder characterized by IgG4-positive plasma cell tissue infiltration, storiform fibrosis, obliterative phlebitis, and frequently elevated serum IgG4 concentration. The IgG4-RD spectrum includes autoimmune pancreatitis type 1, sclerosing cholangitis, dacryoadenitis, sialadenitis, Mikulicz disease, tubulointerstitial nephritis, periaortitis (including a substantial proportion of “idiopathic” retroperitoneal fibrosis), Riedel thyroiditis, and other manifestations. Recognition of the IgG4-RD subset substantially affects management because IgG4-RD typically demonstrates excellent response to corticosteroid therapy and increasing evidence for rituximab efficacy.
The remaining “true idiopathic” IRF cases (approximately 50%) lack IgG4-RD features and likely represent a heterogeneous group with various inflammatory mechanisms. Secondary retroperitoneal fibrosis — distinct from idiopathic IRF — accounts for approximately 30% of all retroperitoneal fibrosis cases and includes medication-related (ergot derivatives, methysergide, beta-blockers, methyldopa, hydralazine), malignancy-related (lymphoma, retroperitoneal tumors with desmoplastic reaction), infectious (tuberculosis, fungal), radiation-induced, and aortic atherosclerotic causes. The distinction between idiopathic and secondary forms is critical for management because secondary disease requires identification and treatment of the underlying cause rather than empiric immunosuppression.
The clinical consequences of the periaortic fibrous plaque include:
- Ureteric encasement (~80% of patients) — fibrous tissue surrounds and progressively obstructs one or both ureters, typically at the pelvic brim level, producing hydronephrosis, post-renal acute kidney injury, and eventual chronic kidney disease if untreated.
- Vascular compression — inferior vena cava obstruction (lower extremity edema, deep vein thrombosis), aortic involvement (claudication, abdominal pain).
- Constitutional symptoms — low-grade fever, weight loss, fatigue, malaise reflecting the underlying inflammatory process.
- Back or flank pain — often the presenting symptom, ranging from dull persistent ache to severe.
- Elevated inflammatory markers — ESR and CRP elevation in most patients during active disease.
The clinical importance of identifying secondary forms — particularly malignancy-related retroperitoneal fibrosis — cannot be overstated. Approximately 8% of apparently idiopathic retroperitoneal fibrosis cases ultimately prove to be lymphoma or other malignancy with desmoplastic reaction. Atypical imaging features (extension above renal arteries, asymmetric distribution, marked enhancement, anterior IVC displacement, associated lymphadenopathy) should prompt biopsy before empiric immunosuppression, because steroid therapy without tissue diagnosis can mask underlying malignancy and delay appropriate treatment.
S2. Diagnostic Criteria and Imaging Workup
Diagnosis combines characteristic cross-sectional imaging showing the periaortic fibrous plaque with consequences (hydronephrosis, medial ureteric deviation), exclusion of secondary causes, and selective biopsy when imaging features are atypical or malignancy cannot be confidently excluded. The IgG4-RD subset is characterized by serum IgG4 elevation and IgG4-positive plasma cell tissue infiltration when biopsy is obtained.
| Investigation | Finding in Ormond disease | Clinical role |
|---|---|---|
| Contrast-enhanced CT abdomen and pelvis | Periaortic soft tissue plaque around infrarenal aorta extending laterally; hydronephrosis frequently bilateral; medial ureteric deviation | First-line imaging diagnostic |
| MRI abdomen | T1 hypointense, T2 variable (active disease often hyperintense, burnt-out hypointense), contrast enhancement | Tissue characterization; serial activity assessment |
| FDG PET-CT | Increased FDG uptake in active inflammatory disease; helps distinguish active from burnt-out fibrosis | Activity assessment; treatment response monitoring |
| Serum IgG4 concentration | Elevated in ~50% of patients (IgG4-RD subset); supports IgG4-RD framework | IgG4-RD identification |
| Tissue biopsy with IgG4 immunohistochemistry | Storiform fibrosis with IgG4-positive plasma cells (IgG4/IgG ratio >40%) in IgG4-RD subset; lymphoplasmacytic infiltrate without specific features in true idiopathic disease | Reserved for atypical features or malignancy exclusion |
| Detailed medication history | Ergot derivatives, methysergide, beta-blockers, methyldopa, hydralazine — identifies secondary RPF | Mandatory exclusion of medication-related cause |
| CT chest, full body imaging | Identifies systemic malignancy producing secondary RPF | Excludes malignancy |
| Renal function and creatinine | AKI from obstruction; CKD in chronic untreated cases | Severity assessment |
| Urinalysis | Generally normal; obstruction features when present | Routine workup |
| ESR, CRP, CBC | Elevated inflammatory markers in active disease; anemia of chronic inflammation | Activity markers; treatment response tracking |
| ANA, ANCA, complement | Generally negative in primary RPF; excludes autoimmune mimics | Differential diagnosis |
| Tuberculin skin test / IGRA | Excludes tuberculous RPF | Pre-immunosuppression screening + differential |
| Bone scan or skeletal survey if elderly | Excludes prostate cancer with desmoplastic reaction | Selected workup |
| Echocardiogram in selected cases | Assesses for periaortitis with cardiac involvement | If clinical features suggest extension |
The CT and MRI findings of Ormond disease are reasonably characteristic when classical: confluent periaortic soft tissue plaque starting below the renal arteries and extending laterally to encase the ureters at the pelvic brim level, producing hydronephrosis often bilaterally, with medial deviation of the ureters being characteristic. The plaque typically does not displace the inferior vena cava anteriorly (a feature that distinguishes from malignant secondary RPF where anterior IVC displacement is more common). Atypical features warranting biopsy include extension above the renal arteries, asymmetric or eccentric distribution, marked contrast enhancement, anterior IVC displacement, associated lymphadenopathy beyond the immediate retroperitoneum, and bone lesions.
S3. Treatment Strategy from Ureteric Drainage to Rituximab
Treatment of Ormond disease combines acute relief of urinary obstruction, glucocorticoid therapy as cornerstone medical management, steroid-sparing immunosuppression for relapsing or steroid-dependent disease, and rituximab for refractory disease particularly in the IgG4-RD subset. The therapeutic approach has evolved substantially from the historical emphasis on extensive surgical ureterolysis to the contemporary medical-first approach with surgery reserved for specific anatomic indications.
Acute urinary drainage
Acute ureteric obstruction with hydronephrosis and renal dysfunction requires urgent urinary drainage before disease-modifying therapy can be effective. Options include:
- Retrograde ureteric stent placement via cystoscopy — typically first-line for acute drainage; double-J stents provide drainage while ureteric fibrosis resolves on medical therapy.
- Percutaneous nephrostomy — alternative when retrograde stent placement fails or proximal obstruction prevents cystoscopic access; can be converted to internal drainage when medical therapy reduces fibrotic burden.
- Surgical ureterolysis with omental wrap — historical primary intervention now largely replaced by stent placement plus medical therapy; reserved for fibrosis not responsive to medical management or anatomically severe disease.
Glucocorticoid therapy — cornerstone
Prednisone at 0.5–1 mg/kg/day PO (typically 40–60 mg/day in adults) with gradual taper over 6–12 months is the established cornerstone medical therapy with response rates of approximately 80–90% in well-selected patients. Most patients show inflammatory marker improvement within weeks and radiographic reduction in plaque size within 3 months. The taper schedule extends over months because rapid taper produces relapse in many patients. Maintenance prednisone at low doses (5–10 mg/day) is often required long-term in patients who relapse during initial taper.
Steroid-sparing immunosuppression
For patients with relapsing disease, steroid dependence, or contraindications to high-dose steroids, steroid-sparing agents include:
- Methotrexate at 15–25 mg PO or SC weekly with folic acid — most-used steroid-sparing agent.
- Mycophenolate mofetil at 1–1.5 g PO BID — alternative steroid-sparing therapy.
- Azathioprine at 2 mg/kg/day PO — historical steroid-sparing option.
- Tamoxifen at 20–40 mg/day PO — historical therapy with limited contemporary use; mechanism involves anti-fibrotic effect on retroperitoneal fibroblasts. Now largely supplanted by other agents but occasionally used in specific contexts.
Rituximab for refractory and IgG4-RD subset
Rituximab at 1000 mg IV × 2 doses 2 weeks apart, repeated every 6 months is the preferred therapy for refractory disease and is increasingly used as initial therapy in confirmed IgG4-related disease cases. Multiple case series and consensus recommendations support rituximab efficacy in IgG4-RD including the retroperitoneal manifestation, with response rates exceeding 80% in published cohorts. The IgG4-RD International Consensus Guidance specifically recommends rituximab for severe or refractory disease.
| Approach | Best evidence niche | Practical positioning |
|---|---|---|
| Retrograde ureteric stent placement | Acute hydronephrosis with renal dysfunction | First-line urgent drainage |
| Percutaneous nephrostomy | When retrograde stent fails | Alternative drainage |
| Surgical ureterolysis with omental wrap | Medical therapy failure or severe anatomic disease | Reserved for selected cases |
| Prednisone 0.5-1 mg/kg/day with 6-12 month taper | Cornerstone medical therapy | ~80-90% response rate |
| Low-dose prednisone maintenance | Relapse during taper | 5-10 mg/day long-term in many patients |
| Methotrexate steroid-sparing | Relapsing or steroid-dependent disease | First-line steroid-sparing |
| Mycophenolate mofetil | Steroid-sparing alternative | Selected based on tolerability |
| Azathioprine | Historical steroid-sparing option | Less commonly used now |
| Tamoxifen | Historical anti-fibrotic option | Limited contemporary use |
| Rituximab 1000 mg × 2 q6 months | Refractory disease, IgG4-RD subset | Preferred for IgG4-RD; emerging first-line |
| Cyclophosphamide | Severe refractory disease | Rarely used; selected cases |
| FDG PET-CT response assessment | Treatment response monitoring | Tracks active vs burnt-out disease |
| Ureteric stent removal trial | After medical therapy reduces plaque | Sequential stent removal as fibrosis resolves |
S4. Monitoring and Relapse Surveillance
Monitoring addresses treatment response (clinical, biochemical, radiographic), relapse detection during and after taper, urinary drainage adequacy, and IgG4-RD multisystem surveillance in the IgG4-RD subset.
| Domain | Recommended interval | Trigger for intervention |
|---|---|---|
| Clinical assessment (back pain, constitutional symptoms) | q1 month × 3 months; q3 months × 1 year; q6 months thereafter | Recurrent symptoms → workup for relapse |
| Inflammatory markers (CRP, ESR) | q1-3 months during taper | Rising markers → assess for relapse |
| CT or MRI abdomen and pelvis | Baseline; 3-6 months; periodic thereafter (q6-12 months) | Plaque growth or new findings |
| FDG PET-CT (selected) | Baseline if available; for treatment response assessment | Persistent or new FDG uptake |
| Renal function (creatinine, eGFR) | Monthly × 3 months; q3 months thereafter | Declining function → drainage assessment |
| Ureteric stent management | Stent changes per urology protocol | Stent dysfunction or obstruction |
| Trial of stent removal | After 3-6 months of effective therapy | Continued obstruction → re-stent |
| Serum IgG4 (IgG4-RD subset) | q3-6 months | Rising IgG4 may herald relapse |
| IgG4-RD multisystem screening (salivary, lacrimal, pancreas, biliary, lung) | Annually in IgG4-RD subset | New organ involvement |
| Bone density (DEXA) on chronic steroids | Baseline; q1-2 years | Osteoporosis prevention |
| Cataract and glaucoma screening on steroids | Annually | Steroid-related ocular complications |
| Glucose monitoring on steroids | Each visit | Steroid-induced diabetes |
Long-term outcomes have substantially improved with the contemporary medical-first approach combined with effective ureteric drainage. Approximately 80-90% of patients achieve initial response to corticosteroid therapy, with relapse occurring in approximately 50% during or after taper. Sustained remission is achievable with steroid-sparing maintenance therapy or rituximab in relapsing cases. Renal function preservation depends on timely ureteric drainage and effective medical therapy reducing the fibrotic burden. Patients who achieve effective treatment with sustained remission generally maintain good renal function and quality of life long-term.
S5. Clinical Commentary and Referral Triggers
The most clinically consequential reframe in Ormond disease over the past two decades has been the recognition that approximately 50% of cases represent the retroperitoneal manifestation of IgG4-related disease. This reframe has substantial implications for workup (serum IgG4 measurement, tissue IgG4 staining when biopsy is obtained), multi-organ surveillance, and treatment selection (increasing evidence for rituximab efficacy particularly in IgG4-RD). The integration of IgG4-RD framework into Ormond disease management has improved outcomes for patients with the IgG4-RD subset who previously may have been managed with less effective therapy.
The second clinical reframe is the importance of excluding malignant secondary retroperitoneal fibrosis before empiric immunosuppression. Approximately 8% of apparently idiopathic cases ultimately prove to be lymphoma or other malignancy with desmoplastic reaction, and steroid therapy without tissue diagnosis can mask underlying malignancy and delay appropriate treatment. Atypical imaging features (extension above renal arteries, asymmetric distribution, marked enhancement, anterior IVC displacement) should prompt biopsy before immunosuppression initiation.
- New diagnosis of Ormond disease — for multidisciplinary workup and treatment planning
- Severe bilateral hydronephrosis requiring acute drainage
- Atypical imaging features requiring tissue diagnosis to exclude malignancy
- IgG4-RD diagnosis with multisystem manifestations
- Refractory disease despite corticosteroid and steroid-sparing therapy
- Recurrent relapses requiring rituximab or combination therapy
- Surgical ureterolysis consideration
- Pregnancy with active Ormond disease
- Pediatric or atypical presentations
- Suspected medication-related secondary RPF
Practice Insights — Synthesized Patterns for Ormond Disease Care
(The content below synthesizes published clinical patterns and Ormond disease specialty experience, not first-person case reports.) Across published Ormond disease case series and nephrology referral experience, the disease’s most consistent pitfall is initiating empiric corticosteroid therapy without first excluding malignant secondary retroperitoneal fibrosis through appropriate workup and selective biopsy. Experienced practice has reframed any patient with retroperitoneal soft tissue mass with atypical features (extension above renal arteries, asymmetric distribution, anterior IVC displacement, prominent lymphadenopathy) as warranting tissue biopsy before empiric immunosuppression to avoid steroid-masked malignancy.
What the Guidelines Underweight
Experienced nephrology clinicians have learned that IgG4 testing should be obtained in every new Ormond disease diagnosis at the time of initial workup rather than reserving it for atypical or refractory cases. The substantial proportion of IgG4-RD subset substantially affects long-term management (multisystem surveillance, rituximab as preferred refractory therapy), and identifying the subset at the time of initial diagnosis enables appropriate framing of care from the outset.
Patterns That Repeat Across Series
The recurring delayed-rituximab pattern in published cohorts is an IgG4-RD-positive Ormond disease patient managed with prolonged corticosteroid therapy and multiple steroid-sparing agent cycles before rituximab is finally initiated, by which time substantial steroid toxicity has accumulated. Experienced practice now considers rituximab earlier in IgG4-RD-positive disease — at the first or second relapse rather than after multiple steroid-sparing failures — recognizing the strong evidence for rituximab efficacy in IgG4-RD.
Bedside Heuristic
The established three-element heuristic for any patient with unexplained bilateral hydronephrosis is: (a) obtain contrast-enhanced CT abdomen and pelvis with attention to periaortic soft tissue, (b) measure serum IgG4 to characterize potential IgG4-RD subset, and (c) carefully review imaging for atypical features that would warrant tissue biopsy to exclude malignancy before empiric immunosuppression. The combination ensures comprehensive workup before treatment initiation.
Illustrative Scenario — IgG4-Related Ormond Disease Responding to Rituximab
(Composite teaching scenario assembled from published patterns; not an individual patient.)An illustrative scenario from the literature describes a middle-aged patient presenting with bilateral flank pain, fatigue, and acute kidney injury with creatinine of 3.2 mg/dL. Contrast-enhanced CT abdomen demonstrated bilateral hydronephrosis with periaortic soft tissue plaque encasing the infrarenal aorta and both ureters, characteristic of Ormond disease. Bilateral retrograde ureteric stents were placed urgently with renal function improvement. Serum IgG4 was markedly elevated, and subsequent comprehensive workup revealed bilateral submandibular gland enlargement consistent with associated sialadenitis. Tissue biopsy confirmed IgG4-positive plasma cell infiltrate with storiform fibrosis. Initial prednisone 60 mg/day produced substantial improvement, but relapse during taper at 10 mg/day prompted addition of methotrexate without sustained response. Rituximab 1000 mg × 2 doses repeated every 6 months produced sustained remission with successful prednisone discontinuation and ureteric stent removal at 1 year.
What this scenario teaches: serum IgG4 measurement and IgG4-RD framework should be incorporated into every new Ormond disease diagnosis at initial workup, and rituximab should be considered earlier in IgG4-RD-positive disease rather than after multiple steroid-sparing agent failures.
- Serum IgG4 measurement at every new Ormond diagnosis. Established practice obtains serum IgG4 concentration at the time of initial diagnosis rather than reserving testing for refractory or atypical cases, recognizing that the IgG4-RD subset substantially affects long-term management approach.
- Tissue biopsy before empiric immunosuppression in atypical imaging. Refined practice obtains tissue biopsy when imaging shows atypical features (extension above renal arteries, asymmetric distribution, anterior IVC displacement) before initiating empiric corticosteroid therapy, recognizing that malignant secondary RPF can be masked by steroid therapy.
- Early rituximab consideration in IgG4-RD-positive disease. Experienced practice considers rituximab at the first or second relapse in IgG4-RD-positive Ormond disease rather than after multiple steroid-sparing agent failures, recognizing the strong evidence for rituximab efficacy in IgG4-RD.
- Comprehensive medication review for secondary RPF. Refined practice obtains detailed medication history at diagnosis, with attention to ergot derivatives, methysergide, beta-blockers, methyldopa, and hydralazine that can produce secondary retroperitoneal fibrosis requiring medication discontinuation rather than immunosuppression.
S7. Frequently Asked Questions
- Post-Renal AKI from Urinary Tract Obstruction: Recognition, Decompression, and Post-Obstructive Diuresis Management
- Anemia of CKD: ESA, HIF-PH Inhibitors, Iron Strategy, Hb Targets
- Hyponatremia: Diagnostic Algorithm, Tonicity Assessment, and Safe Correction
- Hyperkalemia: ECG Recognition, Calcium Stabilization, Potassium Shift, and Definitive Removal
- Hypomagnesemia: Diagnosis, Causes, and Replacement Strategy
- Continuous Renal Replacement Therapy (CRRT): Modalities, Dosing, and Anticoagulation in the ICU